The Asia-Pacific Diabetes Care Devices Market was valued at USD 12.2 billion in 2024 and is estimated to grow at a CAGR of 12.5% to reach USD 39 billion by 2034.
Asia-Pacific region is experiencing a significant rise in diabetes, making it one of the most affected regions globally. Factors such as rapid urbanization, sedentary work environments, and increased consumption of high-calorie processed foods have contributed to the growing number of individuals diagnosed with both Type 1 and Type 2 diabetes.
Major players in the Asia-Pacific diabetes care devices market are Sinocare, Eli Lilly and Company, Nova Biomedical, Bionime, Novo Nordisk, B. Braun Melsungen, Sanofi, Platinum Equity Advisors, Medtronic, Abbott Laboratories, ARKRAY, Ascensia Diabetes Care, F. Hoffmann-La Roche, Insulet, Dr. Reddy’s Laboratories, Becton, Dickinson and Company.
To build a strong foothold in the Asia-Pacific diabetes care devices market, companies are embracing a multi-tiered strategy focused on accessibility, innovation, and regional adaptability. Localization remains critical, with firms customizing device features, pricing, and user interfaces to fit cultural preferences and economic conditions across diverse markets. Strategic partnerships with hospitals, pharmacies, and digital health platforms help expand reach and reinforce brand credibility.
This product will be delivered within 2-4 business days.
Asia-Pacific region is experiencing a significant rise in diabetes, making it one of the most affected regions globally. Factors such as rapid urbanization, sedentary work environments, and increased consumption of high-calorie processed foods have contributed to the growing number of individuals diagnosed with both Type 1 and Type 2 diabetes.
Rising Adoption of Devices
The devices segment held a notable share in 2024, encompassing a wide range of products such as blood glucose monitors, insulin delivery systems, lancets, and continuous glucose monitors (CGMs). As diabetes rates climb across the region, demand for reliable, easy-to-use devices is accelerating across both urban and rural populations. Manufacturers are focusing on integrated systems that offer automated insulin dosing, Bluetooth connectivity, and app-based health tracking to improve patient adherence and outcomes.Homecare to Gain Traction
The homecare segment generated significant revenues in 2024 as the region prefers to manage diabetes from the comfort of their homes. With the rising cost of clinical visits and growing emphasis on self-care, home-use devices like glucometers, insulin pens, and wearable CGMs are seeing strong adoption. Companies are prioritizing device portability, ease of use, and real-time connectivity in their product development strategies.China to Emerge as a Lucrative Region
China diabetes care devices market held a notable share in 2024, driven by a massive diabetic population exceeding 140 million and increasing health consciousness among middle-income consumers. Chinese consumers are also becoming more receptive to wearable and connected devices that support long-term disease management. To strengthen their foothold, leading companies are localizing product offerings, forming joint ventures with Chinese healthcare firms, and navigating regulatory pathways to secure early market access.Major players in the Asia-Pacific diabetes care devices market are Sinocare, Eli Lilly and Company, Nova Biomedical, Bionime, Novo Nordisk, B. Braun Melsungen, Sanofi, Platinum Equity Advisors, Medtronic, Abbott Laboratories, ARKRAY, Ascensia Diabetes Care, F. Hoffmann-La Roche, Insulet, Dr. Reddy’s Laboratories, Becton, Dickinson and Company.
To build a strong foothold in the Asia-Pacific diabetes care devices market, companies are embracing a multi-tiered strategy focused on accessibility, innovation, and regional adaptability. Localization remains critical, with firms customizing device features, pricing, and user interfaces to fit cultural preferences and economic conditions across diverse markets. Strategic partnerships with hospitals, pharmacies, and digital health platforms help expand reach and reinforce brand credibility.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Product, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Country, 2021-2034 ($ Mn)
Chapter 8 Company Profiles
Companies Mentioned
The key companies profiled in this Asia-Pacific Diabetes Care Devices market report include:- Abbott Laboratories
- ARKRAY
- Ascensia Diabetes Care
- B. Braun Melsungen
- Becton, Dickinson and Company
- Bionime
- Dr. Reddy’s Laboratories
- Eli Lilly and Company
- F. Hoffmann-La Roche
- Insulet
- Medtronic
- Nova Biomedical
- Novo Nordisk
- Platinum Equity Advisors
- Sanofi
- Sinocare
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | September 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 12.2 Billion |
| Forecasted Market Value ( USD | $ 39 Billion |
| Compound Annual Growth Rate | 12.5% |
| Regions Covered | Asia Pacific |
| No. of Companies Mentioned | 17 |
